Tag : Opdivo

Latest News

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial

Newsemia
PRINCETON, N.J., & ALAMEDA, Calif.–(BUSINESS WIRE)—- $BMY #BMS–Opdivo in Combination with CABOMETYX Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma…. Source link...
Latest News

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial

Newsemia
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which...
Latest News

ESMO 2020 : Cabometyx® (cabozantinib) en association avec Opdivo® (nivolumab) démontre des bénéfices significatifs en termes de survie chez les patients atteints d’un carcinome du rein avancé dans l’étude pivotale de Phase III CheckMate 9ER

Newsemia
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext : IPN ; ADR : IPSEY) a annoncé aujourd’hui la première présentation des résultats de l’étude pivotale de Phase III...
Latest News

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

Newsemia
PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #BMS–CheckMate -649 Meets Primary Endpoints Source link...
Latest News

Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma

Newsemia
PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #BMS–Opdivo Plus Yervoy Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma Source link...
Latest News

Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced or Metastatic Renal Cell Carcinoma

Newsemia
PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #BMS–Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated...
Latest News

Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Newsemia
PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #BMS–Opdivo Plus Yervoy Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic RCC Source link...
Latest News

Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb’s Opdivo® (Nivolumab)

Newsemia
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate In Combination with Bristol-Myers Squibb’s Opdivo Source link...
Latest News

Opdivo receives FDA approval as first Immuno-Oncology treatment option for small cell lung cancer

Newsemia
Bristol-Myers Squibb Company today announced that Opdivo received approval from the U.S. Food and Drug Administration as the first and only Immuno-Oncology treatment option for...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World